Eli Lilly and Company (NYSE:LLY) Shares Sold by Walker Asset Management LLC

Walker Asset Management LLC decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.2% during the first quarter, HoldingsChannel reports. The firm owned 664 shares of the company’s stock after selling 29 shares during the quarter. Walker Asset Management LLC’s holdings in Eli Lilly and Company were worth $548,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Ibex Wealth Advisors increased its stake in shares of Eli Lilly and Company by 6.1% in the first quarter. Ibex Wealth Advisors now owns 12,345 shares of the company’s stock worth $10,196,000 after acquiring an additional 710 shares during the period. First National Bank of Mount Dora Trust Investment Services grew its position in Eli Lilly and Company by 42.0% during the first quarter. First National Bank of Mount Dora Trust Investment Services now owns 14,093 shares of the company’s stock valued at $11,640,000 after buying an additional 4,168 shares during the period. Sonora Investment Management Group LLC grew its position in Eli Lilly and Company by 4.3% during the first quarter. Sonora Investment Management Group LLC now owns 3,050 shares of the company’s stock valued at $2,519,000 after buying an additional 127 shares during the period. Accurate Wealth Management LLC lifted its holdings in Eli Lilly and Company by 2.2% during the first quarter. Accurate Wealth Management LLC now owns 4,273 shares of the company’s stock valued at $3,529,000 after purchasing an additional 93 shares in the last quarter. Finally, Ayrshire Capital Management LLC lifted its holdings in Eli Lilly and Company by 1.9% during the first quarter. Ayrshire Capital Management LLC now owns 7,827 shares of the company’s stock valued at $6,464,000 after purchasing an additional 145 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and decreased their price target for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday. Wells Fargo & Company reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Hsbc Global Res cut shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. Finally, Guggenheim reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Friday, May 23rd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,011.37.

Eli Lilly and Company Trading Up 0.5%

Shares of LLY stock opened at $773.59 on Tuesday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market capitalization of $733.16 billion, a P/E ratio of 66.06, a price-to-earnings-growth ratio of 1.40 and a beta of 0.40. The company has a 50 day moving average price of $769.95 and a 200 day moving average price of $800.81. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. During the same quarter in the prior year, the firm earned $2.58 EPS. The firm’s revenue was up 45.2% compared to the same quarter last year. Equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a $1.50 dividend. The ex-dividend date is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.